Health Tech Capitol | High-priced drug development deal for Arrowhead Pharmaceuticals takes effect
16456
post-template-default,single,single-post,postid-16456,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

High-priced drug development deal for Arrowhead Pharmaceuticals takes effect

02 Nov High-priced drug development deal for Arrowhead Pharmaceuticals takes effect

Posted at 10:54h in Uncategorized by
0 Likes

Arrowhead Pharmaceuticals has finalized its agreement with Janssen Pharmaceuticals that’s worth $250 million for Arrowhead, just to start.

The waiting period under the Hart-Scott Rodino Antitrust Act expired with no problems expressed by regulators, the companies said Wednesday.

Janssen — part of the Johnson & Johnson conglomerate — will give Arrowhead $175 million upfront for the worldwide exclusive license for Arrowhead’s ARO-HBV drug to treat chronic hepatitis B and options to work with Arrowhead on drugs to fight up to three more diseases.

Read more at the Wisconsin State Journal

No Comments

Sorry, the comment form is closed at this time.